![Robert H. Tidwell](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert H. Tidwell
Keine laufenden Positionen mehr
Karriereverlauf von Robert H. Tidwell
Ehemalige bekannte Positionen von Robert H. Tidwell
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Cell Genesys, Inc.
![]() Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Corporate Officer/Principal | 01.08.2000 | 14.10.2009 |
Calydon, Inc.
![]() Calydon, Inc. Medical SpecialtiesHealth Technology Part of ANI Pharmaceuticals, Inc., Calydon, Inc. develops therapeutic products for cancer. The company is based in Sunnyvale, CA. Calydon was acquired by Cell Genesys, Inc. on September 05, 2001 for $17.68 million. | Corporate Officer/Principal | 01.01.1998 | 01.01.2000 |
ALSERES PHARMACEUTICALS, INC. | Geschäftsführer | 01.01.1993 | 01.01.1994 |
Genetics Institute LLC
![]() Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Vertrieb & Marketing | 01.01.1988 | 01.01.1993 |
ELI LILLY AND COMPANY | Corporate Officer/Principal | 01.01.1969 | 01.01.1985 |
QUALIGEN THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2011 | - |
Ausbildung von Robert H. Tidwell
The Ohio State University | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 8 |
Operativ
Corporate Officer/Principal | 4 |
Chief Operating Officer | 1 |
Sales & Marketing | 1 |
Sektoral
Health Technology | 7 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ALSERES PHARMACEUTICALS, INC. | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
Private Unternehmen | 4 |
---|---|
Cell Genesys, Inc.
![]() Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Calydon, Inc.
![]() Calydon, Inc. Medical SpecialtiesHealth Technology Part of ANI Pharmaceuticals, Inc., Calydon, Inc. develops therapeutic products for cancer. The company is based in Sunnyvale, CA. Calydon was acquired by Cell Genesys, Inc. on September 05, 2001 for $17.68 million. | Health Technology |
Genetics Institute LLC
![]() Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Ritter Pharmaceuticals, Inc.
![]() Ritter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA. | Health Technology |
- Börse
- Insiders
- Robert H. Tidwell
- Erfahrung